var data={"title":"Dobutamine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dobutamine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6059?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dobutamine-drug-information\" class=\"drug drug_general\">see &quot;Dobutamine: Drug information&quot;</a> and <a href=\"topic.htm?path=dobutamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dobutamine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161958\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dobutamine Injection, USP;</li>\n      <li>Dobutrex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058084\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenergic Agonist Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sympathomimetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442333\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hemodynamic support: </b>Continuous IV or intraosseous infusion: Initial: 0.5 to 1 mcg/kg/minute; titrate gradually every few minutes until desired response achieved; usual range: 2 to 20 mcg/kg/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058078\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=dobutamine-drug-information\" class=\"drug drug_general\">see &quot;Dobutamine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Hemodynamic support: </b>Infants, Children, and Adolescents: Continuous IV or intraosseous infusion: Initial: 0.5 to 1 mcg/kg/minute, titrate gradually every few minutes until desired response achieved; usual range: 2 to 20 mcg/kg/minute (PALS [Kleinman 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cardiac decompensation:</b> IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 0.5 to 1 mcg/kg/minute (per the manufacturer); may also initiate at higher doses (eg, 2.5 mcg/kg/minute) depending on severity of decompensation with titration to desired response (Leier 1977)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose: 2 to 20 mcg/kg/minute. <b>Note:</b> In patients with heart failure, lower doses are preferred to minimize adverse effects (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum dose: 40 mcg/kg/minute. The ACCF/AHA 2013 heart failure guidelines and the Surviving Sepsis Campaign recommend a maximum dose of 20 mcg/kg/minute (ACCF/AHA [Yancy 2013]; SCCM [Dellinger 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Advanced Cardiovascular Life Support (ACLS) guideline recommendation (in the immediate postcardiac arrest care setting):</b> IV infusion: Initial: 5 to 10 mcg/kg/minute; titrate to effect (AHA [Peberdy 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161937\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (250 mL); 2 mg/mL (250 mL); 4 mg/mL (250 mL); 250 mg/20 mL (20 mL); 500 mg/40 mL (40 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161922\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058088\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Administer as a continuous IV infusion via an infusion device; administer into large vein.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by the concentration (mcg/mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471791\" class=\"block uicn drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 1,000 <b>mcg</b>/mL, 2,000 <b>mcg</b>/mL, <b>or</b> 4,000 <b>mcg</b>/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471790\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Premixed solutions available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>IV infusion:</b> 1,000 <b>mcg</b>/mL, 2,000 <b>mcg</b>/mL, <b>or</b> 4,000 <b>mcg</b>/mL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3051658\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Stability of parenteral admixture at room temperature (25&deg;C) is 48 hours; at refrigeration (4&deg;C) stability is 7 days. Remix solution every 24 hours. Pink discoloration of solution indicates slight oxidation but no significant loss of potency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058087\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Short-term management of patients with cardiac decompensation (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162009\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">DOBUTamine may be confused with DOPamine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F162006\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Cardiovascular: Ventricular premature contractions (5%; dose related), angina pectoris (1% to 3%), chest pain (1% to 3%; nonspecific), palpitations (1% to 3%), hypotension, increased blood pressure, increased heart rate, localized phlebitis, ventricular ectopy (increased)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache (1% to 3%), paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin necrosis (isolated cases)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Decreased serum potassium (slight)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Nausea (1% to 3%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Thrombocytopenia (isolated cases) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Local inflammation, local pain (from infiltration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Leg cramps (mild) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Dyspnea (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever (1% to 3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161944\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to dobutamine or sulfites (some contain sodium metabisulfate), or any component of the formulation; hypertrophic cardiomyopathy with outflow tract obstruction (formerly known as idiopathic hypertrophic subaortic stenosis [IHSS])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-right:2em;\">\n      <b>Note:</b> When utilized for stress testing, additional contraindications according to the American Society of Nuclear Cardiology (ASNC) include patients with recent (&lt;1 week) MI, unstable angina, severe aortic stenosis, atrial tachyarrhythmias with uncontrolled ventricular response, prior history of ventricular tachycardia, uncontrolled hypertension (&gt;200/110 mm Hg), aortic dissection or large aortic aneurysm, and patients on beta blockers where heart rate and inotropic responses to dobutamine will be attenuated (ASNC [Henzlova 2009])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161926\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: Ventricular arrhythmias, including nonsustained ventricular tachycardia and supraventricular arrhythmias, have been reported (Tisdale1995). Observe closely for arrhythmias in patients with acute heart failure; sudden cardiac death has been observed (O&rsquo;Connor 1999; Pickworth 1992; Young 2000). Ensure that ventricular rate is controlled in atrial fibrillation/flutter before initiating; may increase ventricular response rate. In heart transplant candidates, institute appropriate measures to protect patient against risks of sudden cardiac death (Young 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood pressure effects: An increase in blood pressure is more common due to augmented cardiac output, but occasionally a patient may become hypotensive.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure complications: An increased risk of hospitalization and death has been observed with prolonged use in New York Heart Association Class III/IV heart failure patients (O&rsquo;Connor 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tachycardia: May cause dose-related increases in heart rate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ventricular ectopy: May exacerbate ventricular ectopy (dose-related).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aortic stenosis: Ineffective therapeutically in the presence of mechanical obstruction such as severe aortic stenosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy to minimize the risk of arrhythmias (ACC/AHA/ESC [Zipes 2006]; Tisdale 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypovolemia: If needed, correct hypovolemia first to optimize hemodynamics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Active myocardial ischemia/myocardial infarction (post): Use with caution in patients with active myocardial ischemia or recent myocardial infarction; can increase myocardial oxygen demand.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Monoamine oxidase inhibitors (MAO-I): Use with extreme caution in patients taking MAO inhibitors; prolong hypertension may result from concurrent use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sodium sulfite: Product may contain sodium sulfite.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; start at lower end of the dosage range.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-term therapy: According to the ACCF/AHA 2013 heart failure guidelines, long-term use of intravenous inotropic therapy without a specific indication or for reasons other than palliation is potentially harmful (ACCF/AHA [Yancy 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299223\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of COMT</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161931\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13243&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of DOBUTamine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">COMT Inhibitors: May decrease the metabolism of COMT Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161933\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13314045\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Dobutamine should not be used as a diagnostic agent during stress testing in pregnant women (Regitz-Zagrosek 2011). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Appropriate medications should not be withheld due to concerns of fetal teratogenicity. Dobutamine use during the post-resuscitation phase may be considered; however, the effects of inotropic support on the fetus should also be considered. Doses and indications should follow current Advanced Cardiovascular Life Support (ACLS) guidelines  (Jeejeebhoy [AHA] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058083\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, ECG, heart rate, CVP, MAP, urine output; if pulmonary artery catheter is in place, monitor CI, PCWP, RAP, and SVR. Dobutamine lowers central venous pressure and wedge pressure but has little effect on pulmonary vascular resistance.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161925\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Dobutamine, a racemic mixture, stimulates myocardial beta<sub>1</sub>-adrenergic receptors primarily by the (+) enantiomer and some alpha<sub>1</sub> receptor agonism by the (-) enantiomer, resulting in increased contractility and heart rate, and stimulates both beta<sub>2</sub>- and alpha<sub>1</sub>-receptors in the vasculature. Although beta<sub>2</sub> and alpha<sub>1</sub> adrenergic receptors are also activated, the effects of beta<sub>2</sub> receptor activation may equally offset or be slightly greater than the effects of alpha<sub>1</sub> stimulation, resulting in some vasodilation in addition to the inotropic and chronotropic actions (Leier 1988; Majerus 1989; Ruffolo 1987). Lowers central venous pressure and wedge pressure, but has little effect on pulmonary vascular resistance (Leier 1977; Leier 1978). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161943\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IV: 1 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: 10 to 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: In tissues and hepatically to inactive metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323116\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DOBUTamine in D5W Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (250 mL): $15.03</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161947\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Admeda (UA);</li>\n      <li>Butamine (IL);</li>\n      <li>Cardiject (ID, IN, TH, ZA);</li>\n      <li>Cardiotone (ID);</li>\n      <li>Cardomin (BD, LK, PH);</li>\n      <li>Dexdobu (VN);</li>\n      <li>Dobamin (KR);</li>\n      <li>Dobtan (BR);</li>\n      <li>Dobu-Hameln (PE);</li>\n      <li>Dobucard (MY, PH);</li>\n      <li>Dobuject (AE, BH, CR, CZ, DK, DO, FI, GT, HN, ID, IL, JO, KR, KW, MX, NI, NZ, PA, PH, PK, PL, QA, RU, SA, SE, SG, SV, TW);</li>\n      <li>Dobumin (BD);</li>\n      <li>Dobunex (PH);</li>\n      <li>Doburan (KR, PH, VE);</li>\n      <li>Dobusafe (CO, VN);</li>\n      <li>Dobutamin Hexal (DE, HU);</li>\n      <li>Dobutamin-Ratiopharm (DE);</li>\n      <li>Dobutamine Aguettant (FR);</li>\n      <li>Dobutamine Hydrochloride (GB);</li>\n      <li>Dobutamine Panpharma (FR);</li>\n      <li>Dobutel (PH, TH);</li>\n      <li>Dobutrex (AU, BD, BE, BF, BG, BH, BJ, CH, CI, CR, CZ, DK, DO, EG, ET, FR, GB, GH, GM, GN, GT, HN, HR, HU, IE, IN, IT, JO, KE, KR, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, PA, PY, RU, SA, SC, SD, SE, SI, SL, SN, SV, TN, TR, TZ, UG, VN, ZM, ZW);</li>\n      <li>Dominic (ID);</li>\n      <li>Doxa (PY);</li>\n      <li>Duvig (AR);</li>\n      <li>Easydobu (TW);</li>\n      <li>Gendobu (TW);</li>\n      <li>Inomin (BD);</li>\n      <li>Inotop (AT);</li>\n      <li>Inotrex (GR, PT);</li>\n      <li>Inotrop (ID);</li>\n      <li>Myofast (CO);</li>\n      <li>Posiject (GB, IE);</li>\n      <li>Pusogard (PH);</li>\n      <li>Utamine (TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/23353941/pubmed\" target=\"_blank\" id=\"23353941\">23353941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dobutamine in 5% Dextrose Injection [prescribing information]. Lake Forest, IL: Hospira, Inc.; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dobutamine Injection [prescribing information]. Lake Forest, IL: Hospira, Inc.; 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, &quot;Preparing for Pediatric Emergencies: Drugs to Consider,&quot; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henzlova MJ, Cerqueira MD, Mahmarian JJ, et al. Stress protocols and tracers. <i>J Nucl Cardiol</i>. 2006;13(6):e80-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/17174798/pubmed\" target=\"_blank\" id=\"17174798\">17174798</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &quot;Standard Concentrations of Neonatal Drug Infusions,&quot; <i>ISMP</i>, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeejeebhoy FM, Zelop CM, Lipman S, et al. Cardiac arrest in pregnancy: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/26443610/pubmed\" target=\"_blank\" id=\"26443610\">26443610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &quot;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leier CV, Heban PT, Huss P, Bush CA, Lewis RP. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. <i>Circulation</i>. 1978;58(3 Pt 1):466-475.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/679437/pubmed\" target=\"_blank\" id=\"679437\">679437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. <i>Circulation</i>. 1977;56(3):468-472.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/884803/pubmed\" target=\"_blank\" id=\"884803\">884803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leier CV. Regional blood flow responses to vasodilators and inotropes in congestive heart failure. <i>Am J Cardiol</i>. 1988;62(8):86E-93E.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/2901217/pubmed\" target=\"_blank\" id=\"2901217\">2901217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Majerus TC, Dasta JF, Bauman JL, Danziger LH, Ruffolo RR Jr. Dobutamine: ten years later. <i>Pharmacotherapy</i>. 1989;9(4):245-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/2671957/pubmed\" target=\"_blank\" id=\"2671957\">2671957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). <i>Am Heart J</i>. 1999;138(1 Pt 1):78-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/10385768/pubmed\" target=\"_blank\" id=\"10385768\">10385768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18 Suppl 3):S768-S786.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/20956225/pubmed\" target=\"_blank\" id=\"20956225\">20956225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &quot;Standardizing I.V. Infusion Concentrations: National Survey Results,&quot; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pickworth KK. Long-term dobutamine therapy for refractory congestive heart failure. <i>Clin Pharm</i>. 1992;11(7):618-624.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/1617912/pubmed\" target=\"_blank\" id=\"1617912\">1617912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regitz-Zagrosek V, Blomstrom Lundqvist C, et al. European Society of Gynecology (ESG). ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).<i> Heart Jr</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/21873418 /pubmed\" target=\"_blank\" id=\"21873418 \">21873418 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruffolo RR Jr. The pharmacology of dobutamine. <i>Am J Med Sci</i>. 1987;294(4):244-248.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/3310640/pubmed\" target=\"_blank\" id=\"3310640\">3310640</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Subhedar NV, &quot;Treatment of Hypotension in Newborns,&quot; <i>Semin Neonatolt</i>, 2003, 8(6):413-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/15001113/pubmed\" target=\"_blank\" id=\"15001113\">15001113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. <i>Prog Cardiovasc Dis</i>. 1995;38(2):167-180.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/7568905/pubmed\" target=\"_blank\" id=\"7568905\">7568905</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulationyo</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Young JB, Moen EK. Outpatient parenteral inotropic therapy for advanced heart failure. <i>J Heart Lung Transplant</i>. 2000;19(8 Suppl):S49-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/11016488/pubmed\" target=\"_blank\" id=\"11016488\">11016488</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. <i>Circulation</i>. 2006;114(10):e385-484.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dobutamine-pediatric-drug-information/abstract-text/16935995/pubmed\" target=\"_blank\" id=\"16935995\">16935995</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13243 Version 118.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F161958\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058084\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442333\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058078\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F161937\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F161922\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058088\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Neonatal\" href=\"#F14471791\" class=\"outlineLink\">Usual Infusion Concentrations: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14471790\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F3051658\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058087\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F162009\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F162006\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F161944\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F161926\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299223\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F161931\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F161933\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13314045\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058083\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F161925\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F161943\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323116\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F161947\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13243|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dobutamine-drug-information\" class=\"drug drug_general\">Dobutamine: Drug information</a></li><li><a href=\"topic.htm?path=dobutamine-patient-drug-information\" class=\"drug drug_patient\">Dobutamine: Patient drug information</a></li></ul></div></div>","javascript":null}